Abstract
Neurodegenerative disorders (NDs) are rapidly increasing as population ages. However, successful treatments for NDs have so far been limited and drug delivery to the brain remains one of the major challenges to overcome. There has recently been growing interest in the development of drug delivery systems (DDS) for local or systemic brain administration. DDS are able to improve the pharmacological and therapeutic properties of conventional drugs and reduce their side effects. The present review provides a concise overview of the recent advances made in the field of brain drug delivery for treating neurodegenerative disorders. Examples include polymeric micro and nanoparticles, lipidic nanoparticles, pegylated liposomes, microemulsions and nanogels that have been tested in experimental models of Parkinson’s, Alzheimer’s and Hungtinton’s disease. Overall, the results reviewed here show that DDS have great potential for NDs treatment.
Keywords: Drug delivery systems, neurodegenerative disorders, stereotactic surgery, blood brain barrier, Alzheimer’s disease (AD), pharmacological and therapeutic properties, conventional drugs, neurodegenerative disorders, polymeric micro, lipidic nanoparticles, pegylated liposomes, Parkinson’s disease (PD), microemulsion, drug delivery
Current Pharmaceutical Biotechnology
Title:Brain Drug Delivery Systems for Neurodegenerative Disorders
Volume: 13 Issue: 12
Author(s): E. Garbayo, E. Ansorena and M.J. Blanco-Prieto
Affiliation:
Keywords: Drug delivery systems, neurodegenerative disorders, stereotactic surgery, blood brain barrier, Alzheimer’s disease (AD), pharmacological and therapeutic properties, conventional drugs, neurodegenerative disorders, polymeric micro, lipidic nanoparticles, pegylated liposomes, Parkinson’s disease (PD), microemulsion, drug delivery
Abstract: Neurodegenerative disorders (NDs) are rapidly increasing as population ages. However, successful treatments for NDs have so far been limited and drug delivery to the brain remains one of the major challenges to overcome. There has recently been growing interest in the development of drug delivery systems (DDS) for local or systemic brain administration. DDS are able to improve the pharmacological and therapeutic properties of conventional drugs and reduce their side effects. The present review provides a concise overview of the recent advances made in the field of brain drug delivery for treating neurodegenerative disorders. Examples include polymeric micro and nanoparticles, lipidic nanoparticles, pegylated liposomes, microemulsions and nanogels that have been tested in experimental models of Parkinson’s, Alzheimer’s and Hungtinton’s disease. Overall, the results reviewed here show that DDS have great potential for NDs treatment.
Export Options
About this article
Cite this article as:
Garbayo E., Ansorena E. and Blanco-Prieto M.J., Brain Drug Delivery Systems for Neurodegenerative Disorders, Current Pharmaceutical Biotechnology 2012; 13 (12) . https://dx.doi.org/10.2174/138920112803341761
DOI https://dx.doi.org/10.2174/138920112803341761 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Overview on Potential Neuroprotective Compounds for Management of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Immune Functions of Glia and Neurons in the Central Nervous System
Current Immunology Reviews (Discontinued) Potential of Antibiotics for the Treatment and Management of Parkinson's Disease: An Overview
Current Drug Research Reviews Lower Uric Acid Linked with Cognitive Dysfunction in the Elderly
CNS & Neurological Disorders - Drug Targets Mediterranean Diet and Dementia of the Alzheimer Type
Current Aging Science Thiazoles and Thiazolidinones as Antioxidants
Current Medicinal Chemistry Properties of Neurotoxic Peptides Related to the Bri Gene
Protein & Peptide Letters Applying Epigenetics to Alzheimer’s Disease via the Latent Early–life Associated Regulation (LEARn) Model
Current Alzheimer Research New Kid on the Block: Does Histamine Get Along with Inflammation in Amyotrophic Lateral Sclerosis?
CNS & Neurological Disorders - Drug Targets Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight
Current Neuropharmacology Amyloidogenesis of Natively Unfolded Proteins
Current Alzheimer Research Modulation of Endoplasmic Reticulum Stress: An Opportunity to Prevent Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Retracted: Zebrafish Caspase-3: Molecular Cloning, Characterization, Crystallization and Phylogenetic Analysis
Protein & Peptide Letters Therapeutic Implications for Immunophilin Ligands in the Treatment of Neurodegenerative Diseases
Current Drug Targets - CNS & Neurological Disorders Intrinsically Disordered Domains, Amyloids and Protein Liquid Phases: Evolving Concepts and Open Questions
Protein & Peptide Letters A New Hypothesis of Pathogenesis Based on the Divorce between Mitochondria and their Host Cells: Possible Relevance for Alzheimers Disease
Current Alzheimer Research Coumarin-1,2,3-triazole Hybrid Molecules: An Emerging Scaffold for Combating Drug Resistance
Current Topics in Medicinal Chemistry Intervention of Proliferation and Differentiation of Endogenous Neural Stem Cells in the Neurodegenerative Process of Huntingtons Disease Phenotype
CNS & Neurological Disorders - Drug Targets Davunetide: Peptide Therapeutic in Neurological Disorders
Current Medicinal Chemistry Spatiotemporal Regulation of DNA Replication in the Human Genome and its Association with Genomic Instability and Disease
Current Medicinal Chemistry